Demographic and clinical characteristics of the study population
| Age/sex . | Antiphospholipid antibody profile . | Previous diagnosis . | CAPS involvement . | Treatment . | Outcome (time to recovery) . |
|---|---|---|---|---|---|
| 50/F | IgG aCL 77 GPL IgM aCL negative IgG aβ2GPI 102 U IgM aβ2GPI negative LAC positive | Thrombotic + obstetric PAPS | Kidney, heart, skin, lung | AC + PE + S + IVIG + low-dose aspirin | Complete recovery (20 d) |
| 35/F | IgG aCL 118 GPL IgM aCL negative IgG aβ2GPI 326 U IgM aβ2GPI negative LAC positive | Thrombotic + obstetric PAPS | Skin, liver, lung, right adrenal gland | AC + PE + S + IVIG + low-dose aspirin | Complete recovery (8 d) |
| 29/M | IgG aCL 95 GPL IgM aCL 61 MPL IgG aβ2GPI 101 U IgM aβ2GPI 43 U LAC positive | Antiphospholipid antibody carrier | Brain, kidney, heart, retina, skin | AC + PE + S + IVIG + low-dose aspirin | Complete recovery (10 d) |
| 56/F | IgG aCL 100 GPL IgM aCL negative IgG aβ2GPI 21 U IgM aβ2GPI negative LAC positive | Previous CAPS | Colon, lung, heart | AC + PE + S + IVIG + double anti-platelet therapy | Complete recovery (8 d) |
| 44/F | IgG aCL 30 GPL IgM aCL negative IgG aβ2GPI27 U IgM aβ2GPI negative LAC positive | Thrombotic APS + SLE | Lung, liver, inferior mesenteric artery, infrarenal aorta | AC + PE + S + IVIG | Partial recovery (10 d) Large vessel thrombosis stabilized outcomes |
| 47/F | IgG aCL 69 GPL IgM aCL88 MPL IgG aβ2GPI 101 U IgM aβ2GPI 39 U LAC positive | Thrombotic APS + lupuslike | Kidney, ischemic cholecystitis, left adrenal gland | AC + PE + S | Partial recovery (8 d) Renal failure GFR: 50 mL/min |
| 30/F | IgG aCL 101 GPL IgM aCL 131 MPL IgG aβ2GPI 154 U IgM aβ2GPI 80 U LAC positive | Thrombotic APS | Heart, lung, skin | AC + PE + S + IVIG + low-dose aspirin | Partial recovery (16 d) Cardiomyopathy NYHA class I to II |
| Age/sex . | Antiphospholipid antibody profile . | Previous diagnosis . | CAPS involvement . | Treatment . | Outcome (time to recovery) . |
|---|---|---|---|---|---|
| 50/F | IgG aCL 77 GPL IgM aCL negative IgG aβ2GPI 102 U IgM aβ2GPI negative LAC positive | Thrombotic + obstetric PAPS | Kidney, heart, skin, lung | AC + PE + S + IVIG + low-dose aspirin | Complete recovery (20 d) |
| 35/F | IgG aCL 118 GPL IgM aCL negative IgG aβ2GPI 326 U IgM aβ2GPI negative LAC positive | Thrombotic + obstetric PAPS | Skin, liver, lung, right adrenal gland | AC + PE + S + IVIG + low-dose aspirin | Complete recovery (8 d) |
| 29/M | IgG aCL 95 GPL IgM aCL 61 MPL IgG aβ2GPI 101 U IgM aβ2GPI 43 U LAC positive | Antiphospholipid antibody carrier | Brain, kidney, heart, retina, skin | AC + PE + S + IVIG + low-dose aspirin | Complete recovery (10 d) |
| 56/F | IgG aCL 100 GPL IgM aCL negative IgG aβ2GPI 21 U IgM aβ2GPI negative LAC positive | Previous CAPS | Colon, lung, heart | AC + PE + S + IVIG + double anti-platelet therapy | Complete recovery (8 d) |
| 44/F | IgG aCL 30 GPL IgM aCL negative IgG aβ2GPI27 U IgM aβ2GPI negative LAC positive | Thrombotic APS + SLE | Lung, liver, inferior mesenteric artery, infrarenal aorta | AC + PE + S + IVIG | Partial recovery (10 d) Large vessel thrombosis stabilized outcomes |
| 47/F | IgG aCL 69 GPL IgM aCL88 MPL IgG aβ2GPI 101 U IgM aβ2GPI 39 U LAC positive | Thrombotic APS + lupuslike | Kidney, ischemic cholecystitis, left adrenal gland | AC + PE + S | Partial recovery (8 d) Renal failure GFR: 50 mL/min |
| 30/F | IgG aCL 101 GPL IgM aCL 131 MPL IgG aβ2GPI 154 U IgM aβ2GPI 80 U LAC positive | Thrombotic APS | Heart, lung, skin | AC + PE + S + IVIG + low-dose aspirin | Partial recovery (16 d) Cardiomyopathy NYHA class I to II |
AC, anticoagulant drugs; F, female; GFR, glomerular filtration rate; GPL, G phospholipid units; IgG aCL, immunoglobulin G anticardiolipin; IgM aCL, immunoglobulin M anticardiolipin; IgG aβ2GPI, immunoglobulin G anti-β2 glycoprotein I; IgM aβ2GPI, immunoglobulin M anti-β2 glycoprotein I; IVIG, IV immunoglobulins; LAC, lupus anticoagulant; M, male; MPL, M phospholipid units; NYHA, New York Heart Association; PAPS, primary antiphospholipid syndrome; PE, plasma exchange; S, steroids; SLE, systemic lupus erythematosus.